PMID- 27774267
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210109
IS  - 2055-5822 (Print)
IS  - 2055-5822 (Electronic)
IS  - 2055-5822 (Linking)
VI  - 3
IP  - 1
DP  - 2016 Mar
TI  - The clinical significance of plasma neopterin in heart failure with preserved 
      left ventricular ejection fraction.
PG  - 53-59
AB  - AIMS: Although inflammation plays an important role in the pathogenesis of heart 
      failure (HF), the precise pathophysiological role of inflammation in HF with 
      preserved left ventricular ejection fraction (HFpEF) still remains unclear. 
      Hence, we examined the clinical significance of plasma neopterin, an inflammatory 
      biomarker, in HFpEF patients. METHODS AND RESULTS: In the present study, we 
      recruited consecutive HFpEF patients hospitalized in Kumamoto University 
      Hospital, and further measured plasma neopterin by high-performance liquid 
      chromatography and serum derivatives of reactive oxidative metabolites (DROM), a 
      new biomarker of reactive oxygen species. Compared with risk factors (number of 
      patients, age, sex, and equal incidence of diabetes mellitus, hypertension, and 
      dyslipidemia) -matched non-HF patients (n = 68), plasma neopterin levels, but not 
      serum high-sensitivity C-reactive protein levels, were significantly increased in 
      patients with HFpEF (n = 68) (P < 0.001 and P = 0.15, respectively), accompanied 
      by an elevation in serum DROM levels (P < 0.001). Plasma neopterin levels in New 
      York Heart Association (NYHA) class III/IV HFpEF patients were significantly 
      higher than in NYHA class II patients (P < 0.004). Furthermore, plasma 
      ln-neopterin levels had significant and positive correlation with ln-DROM values 
      (r = 0.57) and parameters of cardiac diastolic dysfunction [the ratio of early 
      transmitral flow velocity to tissue Doppler early diastolic mitral annular 
      velocity (r = 0.34), left atrial volume index (r = 0.17), and B-type natriuretic 
      peptide (r = 0.38)]. Kaplan-Meier analysis showed that the high-neopterin group 
      (>51.5 nM: median value of neopterin in HFpEF patients) had a higher probability 
      of cardiovascular events than the low-neopterin group (log-rank test, P = 0.003). 
      CONCLUSIONS: Plasma neopterin levels significantly increased in HFpEF and 
      correlated with the severity of HF. Furthermore, high neopterin were 
      significantly correlated with future cardiovascular events, indicating that 
      measurement of plasma neopterin might provide clinical benefits for risk 
      stratification of HFpEF patients. (c) 2015 The Authors. ESC Heart Failure published 
      by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
FAU - Yamamoto, Eiichiro
AU  - Yamamoto E
AD  - Faculty of Life Sciences, Department of Cardiovascular Medicine, Graduate School 
      of Medical Sciences Kumamoto University Kumamoto Japan.
FAU - Hirata, Yoshihiro
AU  - Hirata Y
AD  - Faculty of Life Sciences, Department of Cardiovascular Medicine, Graduate School 
      of Medical Sciences Kumamoto University Kumamoto Japan.
FAU - Tokitsu, Takanori
AU  - Tokitsu T
AD  - Faculty of Life Sciences, Department of Cardiovascular Medicine, Graduate School 
      of Medical Sciences Kumamoto University Kumamoto Japan.
FAU - Kusaka, Hiroaki
AU  - Kusaka H
AD  - Faculty of Life Sciences, Department of Cardiovascular Medicine, Graduate School 
      of Medical Sciences Kumamoto University Kumamoto Japan.
FAU - Tabata, Noriaki
AU  - Tabata N
AD  - Faculty of Life Sciences, Department of Cardiovascular Medicine, Graduate School 
      of Medical Sciences Kumamoto University Kumamoto Japan.
FAU - Tsujita, Kenichi
AU  - Tsujita K
AD  - Faculty of Life Sciences, Department of Cardiovascular Medicine, Graduate School 
      of Medical Sciences Kumamoto University Kumamoto Japan.
FAU - Yamamuro, Megumi
AU  - Yamamuro M
AD  - Faculty of Life Sciences, Department of Cardiovascular Medicine, Graduate School 
      of Medical Sciences Kumamoto University Kumamoto Japan.
FAU - Kaikita, Koichi
AU  - Kaikita K
AD  - Faculty of Life Sciences, Department of Cardiovascular Medicine, Graduate School 
      of Medical Sciences Kumamoto University Kumamoto Japan.
FAU - Watanabe, Hiroshi
AU  - Watanabe H
AD  - Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences 
      Kumamoto University Kumamoto Japan.
FAU - Hokimoto, Seiji
AU  - Hokimoto S
AD  - Faculty of Life Sciences, Department of Cardiovascular Medicine, Graduate School 
      of Medical Sciences Kumamoto University Kumamoto Japan.
FAU - Maruyama, Toru
AU  - Maruyama T
AD  - Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences 
      Kumamoto University Kumamoto Japan.
FAU - Ogawa, Hisao
AU  - Ogawa H
AD  - Faculty of Life Sciences, Department of Cardiovascular Medicine, Graduate School 
      of Medical Sciences Kumamoto University Kumamoto Japan.
LA  - eng
PT  - Journal Article
DEP - 20151109
PL  - England
TA  - ESC Heart Fail
JT  - ESC heart failure
JID - 101669191
PMC - PMC5063166
OTO - NOTNLM
OT  - Heart failure with preserved left ventricular function
OT  - Inflammation
OT  - Neopterin
OT  - Reactive oxygen species
EDAT- 2016/10/25 06:00
MHDA- 2016/10/25 06:01
PMCR- 2015/11/09
CRDT- 2016/10/25 06:00
PHST- 2015/05/04 00:00 [received]
PHST- 2015/09/24 00:00 [revised]
PHST- 2015/09/25 00:00 [accepted]
PHST- 2016/10/25 06:00 [pubmed]
PHST- 2016/10/25 06:01 [medline]
PHST- 2016/10/25 06:00 [entrez]
PHST- 2015/11/09 00:00 [pmc-release]
AID - EHF212070 [pii]
AID - 10.1002/ehf2.12070 [doi]
PST - ppublish
SO  - ESC Heart Fail. 2016 Mar;3(1):53-59. doi: 10.1002/ehf2.12070. Epub 2015 Nov 9.